These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 36561085)

  • 21. Glucose-lowering drugs or strategies, atherosclerotic cardiovascular events, and heart failure in people with or at risk of type 2 diabetes: an updated systematic review and meta-analysis of randomised cardiovascular outcome trials.
    Ghosh-Swaby OR; Goodman SG; Leiter LA; Cheng A; Connelly KA; Fitchett D; Jüni P; Farkouh ME; Udell JA
    Lancet Diabetes Endocrinol; 2020 May; 8(5):418-435. PubMed ID: 32333878
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Review of Cardiovascular Outcomes Trials of Glucose-Lowering Therapies and Their Effects on Heart Failure Outcomes.
    Nassif ME; Kosiborod M
    Am J Cardiol; 2019 Dec; 124 Suppl 1():S12-S19. PubMed ID: 31741435
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel Anti-glycemic Drugs and Reduction of Cardiovascular Risk in Diabetes: Expectations Realized, Promises Unmet.
    Flory JH; Ukena JK; Floyd JS
    Curr Atheroscler Rep; 2016 Dec; 18(12):79. PubMed ID: 27817160
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Improvement of glycemic control and reduction of major cardiovascular events in 18 cardiovascular outcome trials: an updated meta-regression.
    Maiorino MI; Longo M; Scappaticcio L; Bellastella G; Chiodini P; Esposito K; Giugliano D
    Cardiovasc Diabetol; 2021 Oct; 20(1):210. PubMed ID: 34663316
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and Cardiovascular Safety of SGLT2 Inhibitors.
    Fernandez CJ; Nevins AG; Nawaz S; Nazir T; Hanna FWF
    Curr Drug Saf; 2021; 16(2):178-196. PubMed ID: 33006538
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cardiovascular effects of non-insulin glucose-lowering agents: a comprehensive review of trial evidence and potential cardioprotective mechanisms.
    Savarese G; Butler J; Lund LH; Bhatt DL; Anker SD
    Cardiovasc Res; 2022 Jul; 118(10):2231-2252. PubMed ID: 34390570
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis.
    Wu JH; Foote C; Blomster J; Toyama T; Perkovic V; Sundström J; Neal B
    Lancet Diabetes Endocrinol; 2016 May; 4(5):411-9. PubMed ID: 27009625
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus.
    Zelniker TA; Wiviott SD; Raz I; Im K; Goodrich EL; Furtado RHM; Bonaca MP; Mosenzon O; Kato ET; Cahn A; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Sabatine MS
    Circulation; 2019 Apr; 139(17):2022-2031. PubMed ID: 30786725
    [TBL] [Abstract][Full Text] [Related]  

  • 29. European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose-lowering drugs in patients with heart failure.
    Seferović PM; Coats AJS; Ponikowski P; Filippatos G; Huelsmann M; Jhund PS; Polovina MM; Komajda M; Seferović J; Sari I; Cosentino F; Ambrosio G; Metra M; Piepoli M; Chioncel O; Lund LH; Thum T; De Boer RA; Mullens W; Lopatin Y; Volterrani M; Hill L; Bauersachs J; Lyon A; Petrie MC; Anker S; Rosano GMC
    Eur J Heart Fail; 2020 Feb; 22(2):196-213. PubMed ID: 31816162
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cardiovascular outcome trials of glucose-lowering medications: an update.
    Home P
    Diabetologia; 2019 Mar; 62(3):357-369. PubMed ID: 30607467
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oral Glucose-lowering Drugs and Cardiovascular Outcomes: From the Negative RECORD and ACCORD to Neutral TECOS and Promising EMPA-REG.
    Tsioufis C; Andrikou E; Thomopoulos C; Papanas N; Tousoulis D
    Curr Vasc Pharmacol; 2017; 15(5):457-468. PubMed ID: 27928947
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use of Sodium-Glucose Cotransporter-2 Inhibitors in Clinical Practice for Heart Failure Prevention and Treatment: Beyond Type 2 Diabetes. A Narrative Review.
    Rao S
    Adv Ther; 2022 Feb; 39(2):845-861. PubMed ID: 34881413
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cardiovascular Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Older Patients in Routine Clinical Care With or Without History of Atherosclerotic Cardiovascular Diseases or Heart Failure.
    Htoo PT; Buse J; Cavender M; Wang T; Pate V; Edwards J; Stürmer T
    J Am Heart Assoc; 2022 Feb; 11(4):e022376. PubMed ID: 35132865
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Glucose-lowering drugs or strategies and cardiovascular outcomes in patients with or at risk for type 2 diabetes: a meta-analysis of randomised controlled trials.
    Udell JA; Cavender MA; Bhatt DL; Chatterjee S; Farkouh ME; Scirica BM
    Lancet Diabetes Endocrinol; 2015 May; 3(5):356-66. PubMed ID: 25791290
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studies.
    Li L; Li S; Deng K; Liu J; Vandvik PO; Zhao P; Zhang L; Shen J; Bala MM; Sohani ZN; Wong E; Busse JW; Ebrahim S; Malaga G; Rios LP; Wang Y; Chen Q; Guyatt GH; Sun X
    BMJ; 2016 Feb; 352():i610. PubMed ID: 26888822
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cardiovascular and renal efficacy and safety of sodium-glucose cotransporter-2 inhibitors in patients without diabetes: a systematic review and meta-analysis of randomised placebo-controlled trials.
    Tsai WC; Hsu SP; Chiu YL; Yang JY; Pai MF; Ko MJ; Tu YK; Hung KY; Chien KL; Peng YS; Wu HY
    BMJ Open; 2022 Oct; 12(10):e060655. PubMed ID: 36241355
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative cardiovascular effectiveness of glucagon-like peptide-1 receptor agonists versus sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes: A population-based cohort study.
    Dong YH; Chang CH; Lin JW; Yang WS; Wu LC; Toh S
    Diabetes Obes Metab; 2022 Aug; 24(8):1623-1637. PubMed ID: 35491533
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Review of cardiovascular outcomes trials of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists.
    North EJ; Newman JD
    Curr Opin Cardiol; 2019 Nov; 34(6):687-692. PubMed ID: 31436559
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Heart Failure End Points in Cardiovascular Outcome Trials of Sodium Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus: A Critical Evaluation of Clinical and Regulatory Issues.
    Butler J; Packer M; Greene SJ; Fiuzat M; Anker SD; Anstrom KJ; Carson PE; Cooper LB; Fonarow GC; Hernandez AF; Januzzi JL; Jessup M; Kalyani RR; Kaul S; Kosiborod M; Lindenfeld J; McGuire DK; Sabatine MS; Solomon SD; Teerlink JR; Vaduganathan M; Yancy CW; Stockbridge N; O'Connor CM
    Circulation; 2019 Dec; 140(25):2108-2118. PubMed ID: 31841369
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of Dipeptidyl Peptidase 4 Inhibitors and Sodium-Glucose Linked coTransporter-2 Inhibitors on cardiovascular events in patients with type 2 diabetes mellitus: A meta-analysis.
    Savarese G; D'Amore C; Federici M; De Martino F; Dellegrottaglie S; Marciano C; Ferrazzano F; Losco T; Lund LH; Trimarco B; Rosano GM; Perrone-Filardi P
    Int J Cardiol; 2016 Oct; 220():595-601. PubMed ID: 27390996
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.